Table 1.
Clinicalpathologic features of breast cancer patients
| Feature | Study cohort | Validation cohort |
|---|---|---|
| Case no (%) | Case no (%) | |
| Tumor type | ||
| IDC | 523(85.88) | 528(85.30) |
| MC | 7(1.15) | 6(0.97) |
| Intraductal carcinoma | 40(6.57) | 45(7.27) |
| Mucinous adenocarcinoma | 14(2.30) | 13(2.10) |
| Others | 25(4.11) | 27(4.36) |
| Tumor size(cm) | ||
| TZ ≤ 2 | 210(34.48) | 200(32.31) |
| 2 < TZ ≤ 5 | 277(45.48) | 289(46.69) |
| TZ > 5 | 29(4.76) | 37(5.98) |
| Unknown | 93(15.27) | 93(15.02) |
| LN involvement | ||
| Positive | 263(43.19) | 278(44.91) |
| Negative | 334(54.84) | 333(53.80) |
| Unknown | 12(1.97) | 8(1.29) |
| ER | ||
| Positive | 313(51.40) | 361(58.32) |
| Negative | 208(34.15) | 207(33.44) |
| Unknown | 88(14.45) | 51(8.24) |
| PR | ||
| Positive | 382(62.73) | 345(55.74) |
| Negative | 134(22.00) | 223(36.03) |
| Unknown | 93(15.27) | 51(8.24) |
| P53 | ||
| Positive | 153(25.12) | 144(23.26) |
| Negative | 353(57.96) | 420(67.85) |
| Unknown | 103(16.91) | 55(8.89) |
| C-erbB-2 | ||
| Positive | 198(32.51) | 187(30.21) |
| Negative | 317(52.05) | 379(61.23) |
| Unknown | 94(15.44) | 53(8.56) |
Abbreviations: IDC = infiltrative ductal carcinoma; MC = medullary carcinoma; LN = lymph node; TZ = tumor size; ER = estrogen receptor; PR = progesterone receptor